Bruker (BRKR)
(Delayed Data from NSDQ)
$64.54 USD
+0.81 (1.27%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $64.54 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$64.54 USD
+0.81 (1.27%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $64.54 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
Zacks News
Bruker (BRKR) Debuts Module on Ultima Multiphoton Microscopes
by Zacks Equity Research
Bruker's (BRKR) NeuraLight 3D Ultra module offers revolutionary 3D holographic photostimulation to support neuroscience and optogenetics research applications.
Bruker (BRKR) to Advance 4D Proteomics With Latest Launch
by Zacks Equity Research
Bruker's (BRKR) timsTOF HT is enhanced for high-throughput, deep and unbiased plasma proteomics, and liquid biopsy biomarker research.
Why Is Bruker (BRKR) Up 6.3% Since Last Earnings Report?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker (BRKR) on strength across the BSI and BEST businesses.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Bruker (BRKR) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Revenue growth across the BSI and BEST businesses drove Bruker's (BRKR) first-quarter 2022 revenues.
Bruker (BRKR) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 19.51% and 3.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Waters (WAT) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 20.69% and 9.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Bruker (BRKR) Unveils New Imaging Tools for Cancer Research
by Zacks Equity Research
Bruker's (BRKR) latest innovation for cancer research is likely to strengthen the company's opportunities in proteomics and spatial biology.
Bruker's (BRKR) Buyout to Expand Mass Spectrometry Prospects
by Zacks Equity Research
Bruker's (BRKR) acquisition of IonSense will reach the DART ionization technology to a wider customer base.
Bruker (BRKR) to Support Biopharma Industries With New Buyout
by Zacks Equity Research
Bruker's (BRKR) recent buyout strengthens the company as a key software and solutions provider for small molecule, biologics and new drug modalities pharma companies.
Here's Why You Should Add Bruker (BRKR) Stock to Your Kitty
by Zacks Equity Research
Bruker's (BRKR) Nano Group microelectronics and semiconductor metrology tools continue to perform well on ongoing strength in bookings and backlog.
Does Bruker (BRKR) Have the Potential to Rally 33% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 33.5% upside potential for Bruker (BRKR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bruker (BRKR) to Improve Spatial Biology With New Launch
by Zacks Equity Research
Bruker's (BRKR) acquired company, Canopy Biosciences, introduced its next generation of ChipCytometry instrumentation for spatial biology.
Bruker (BRKR), Newomics to Co-Market Joint MnESI-MS Platform
by Zacks Equity Research
The maxis II and timsTOF Pro 2 mass spectrometers from Bruker (BRKR) will be marketed with Newomics's MnESI product line.
Here's Why You Should Invest In Bruker (BRKR) Stock Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) better-than-expected revenues and robust segmental performance.
Here's How Much a $1000 Investment in Bruker Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Wall Street Analysts See a 31% Upside in Bruker (BRKR): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 31.4% in Bruker (BRKR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Industry Outlook Highlights: Mettler-Toledo International and Bruker
by Zacks Equity Research
Mettler-Toledo International and Bruker are highlighted in this Industry Outlook article.
2 Stocks to Buy on Rising Demand for Scientific Instruments
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD) and Bruker (BRKR) are gaining from strong life science, pharmaceutical and academic end-market demand as well as rising healthcare spending.
Bruker (BRKR) Q4 Earnings Meet Estimates, Revenues Surpass
by Zacks Equity Research
Robust performance by the BSI and BEST segments drove Bruker's (BRKR) fourth-quarter top line.
Mettler-Toledo (MTD) Q4 Earnings & Sales Beat, Increase Y/Y
by Zacks Equity Research
Mettler-Toledo's (MTD) fourth-quarter 2021 results benefit from robust Laboratory and Industrial segments.
Bruker (BRKR) Meets Q4 Earnings Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 0% and 2.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?